(NASDAQ: ROIV) Roivant Sciences's forecast annual revenue growth rate of 199.46% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 79.33%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.78%.
Roivant Sciences's revenue in 2025 is $23,233,000.On average, 4 Wall Street analysts forecast ROIV's revenue for 2026 to be $15,222,799,815, with the lowest ROIV revenue forecast at $5,927,413,529, and the highest ROIV revenue forecast at $32,232,018,270. On average, 4 Wall Street analysts forecast ROIV's revenue for 2027 to be $27,487,355,919, with the lowest ROIV revenue forecast at $1,529,655,104, and the highest ROIV revenue forecast at $67,946,733,429.
In 2028, ROIV is forecast to generate $580,558,742,629 in revenue, with the lowest revenue forecast at $349,635,452,416 and the highest revenue forecast at $811,482,032,842.